Compared to low-molecular-weight heparin, enoxaparin what was the result of fondaparinux 2.5 mg once daily on the incidence of venous thromboembolism in patients undergoing major orthopedic surgery ?
 At day 30, fondaparinux significantly reduced the occurrence of the primary efficacy outcome (death or recurrent myocardial infarction) by 14% (p=0.008